NO20035236D0 - Farmasöytisk kombinasjon omfattende enten (S) -2-etoksy-3 (4- (2- (4-metansulfonyloksyfenyl) etoksy) fenyl) propansyre eller 3- (4- (2- (4-tert-butoksykarbonylaminofenyl) etoksy) fenyl) - (S) -2- - Google Patents

Farmasöytisk kombinasjon omfattende enten (S) -2-etoksy-3 (4- (2- (4-metansulfonyloksyfenyl) etoksy) fenyl) propansyre eller 3- (4- (2- (4-tert-butoksykarbonylaminofenyl) etoksy) fenyl) - (S) -2-

Info

Publication number
NO20035236D0
NO20035236D0 NO20035236A NO20035236A NO20035236D0 NO 20035236 D0 NO20035236 D0 NO 20035236D0 NO 20035236 A NO20035236 A NO 20035236A NO 20035236 A NO20035236 A NO 20035236A NO 20035236 D0 NO20035236 D0 NO 20035236D0
Authority
NO
Norway
Prior art keywords
ethoxy
phenyl
methanesulfonyloxyphenyl
butoxycarbonylaminophenyl
tert
Prior art date
Application number
NO20035236A
Other languages
English (en)
Inventor
Peter Oehman
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO20035236D0 publication Critical patent/NO20035236D0/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20035236A 2001-06-01 2003-11-25 Farmasöytisk kombinasjon omfattende enten (S) -2-etoksy-3 (4- (2- (4-metansulfonyloksyfenyl) etoksy) fenyl) propansyre eller 3- (4- (2- (4-tert-butoksykarbonylaminofenyl) etoksy) fenyl) - (S) -2- NO20035236D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0101981A SE0101981D0 (sv) 2001-06-01 2001-06-01 Pharmaceutical combination
PCT/SE2002/001037 WO2002096453A1 (en) 2001-06-01 2002-05-30 A pharmaceutical combination comprising either (s)-2-ethoxy-3 [4-(2- {4-methane sulfonyl oxyphenyl} ethoxy)phenyl] propanoic acid or 3-{4-[2- (4-tert-butoxy carbonylamino phenyl) ethoxy] phenyl}-(s)-2-ethoxy propanoic acid and insulin

Publications (1)

Publication Number Publication Date
NO20035236D0 true NO20035236D0 (no) 2003-11-25

Family

ID=20284363

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20035236A NO20035236D0 (no) 2001-06-01 2003-11-25 Farmasöytisk kombinasjon omfattende enten (S) -2-etoksy-3 (4- (2- (4-metansulfonyloksyfenyl) etoksy) fenyl) propansyre eller 3- (4- (2- (4-tert-butoksykarbonylaminofenyl) etoksy) fenyl) - (S) -2-

Country Status (22)

Country Link
US (1) US20040147600A1 (no)
EP (1) EP1401485A1 (no)
JP (1) JP2004532873A (no)
KR (1) KR20040072027A (no)
CN (1) CN1535155A (no)
BR (1) BR0210129A (no)
CA (1) CA2448637A1 (no)
CO (1) CO5540383A2 (no)
CZ (1) CZ20033233A3 (no)
EE (1) EE200300577A (no)
HU (1) HUP0400964A3 (no)
IL (1) IL159034A0 (no)
IS (1) IS7056A (no)
MX (1) MXPA03011012A (no)
NO (1) NO20035236D0 (no)
NZ (1) NZ529812A (no)
PL (1) PL367704A1 (no)
RU (1) RU2003136156A (no)
SE (1) SE0101981D0 (no)
SK (1) SK14712003A3 (no)
WO (1) WO2002096453A1 (no)
ZA (1) ZA200309261B (no)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60308390T2 (de) * 2003-11-28 2007-09-06 Merck Santé Behandlung von Hyperurikämie
AR052888A1 (es) * 2005-01-28 2007-04-11 Lilly Co Eli Uso del agonista alfa de ppar para preparar una formulacion farmaceutica, paquete y dosis unitaria de dicha formulacion
CN102036559A (zh) * 2008-05-19 2011-04-27 雀巢产品技术援助有限公司 降低动物脂质吸收的方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9801992D0 (sv) * 1998-06-04 1998-06-04 Astra Ab New 3-aryl-2-hydroxypropionic acid derivative I
SE9801990D0 (sv) * 1998-06-04 1998-06-04 Astra Ab New 3-aryl propionic acid derivatives and analogs
EP1145717B1 (en) * 2000-04-13 2004-05-12 Pfizer Products Inc. Synergistic effect of glyburide and milrinone

Also Published As

Publication number Publication date
NZ529812A (en) 2006-03-31
CO5540383A2 (es) 2005-07-29
IL159034A0 (en) 2004-05-12
HUP0400964A2 (hu) 2004-08-30
PL367704A1 (en) 2005-03-07
EE200300577A (et) 2004-02-16
SE0101981D0 (sv) 2001-06-01
MXPA03011012A (es) 2004-02-27
EP1401485A1 (en) 2004-03-31
KR20040072027A (ko) 2004-08-16
BR0210129A (pt) 2004-06-08
IS7056A (is) 2003-11-28
CZ20033233A3 (cs) 2004-12-15
HUP0400964A3 (en) 2007-11-28
US20040147600A1 (en) 2004-07-29
RU2003136156A (ru) 2005-05-20
ZA200309261B (en) 2005-02-28
CN1535155A (zh) 2004-10-06
CA2448637A1 (en) 2002-12-05
SK14712003A3 (sk) 2004-08-03
JP2004532873A (ja) 2004-10-28
WO2002096453A1 (en) 2002-12-05

Similar Documents

Publication Publication Date Title
ATE444753T1 (de) Gepufferte flüssige nikotinzusammensetzung zur pulmonalen verabreichung
LU92025I2 (fr) Méthanesulfonate d'éthylester d'acide 3-¬(2-{¬4-(hexyloxy-carbonylamino-imino-méthyl)-phénylamino-méthyl}-1-méthyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino-propionique
EE200300329A (et) Meetod peroraalselt manustatavate epotiloonide biosaadavuse suurendamiseks ning selles kasutatav komplekt, ravimkoostis ja farmatseutiline ravimvorm
FI991485A0 (fi) Uusi farmaseuttinen koostumus
DE60233825D1 (de) BENZOATESÄURE-2-(a-HYDROXYPENTYL)ESTER UND DESSEN HERSTELLUNG UND VERWENDUNG
IS6399A (is) Mulið form (S)-2-etoxý-3-[4-(2-{4-metansúlfonýloxýfenýl}etoxý)fenýl]própanónsýra
MA25658A1 (fr) Sels hydrochlores de 5(4-(2-(n-methyl-n-(2-pyridil) amino) ethoxy) benzyl) thyazolidine-2,4-dione.
NO20043418L (no) Stabiliserte adenovirusformuleringer
IS6400A (is) Kristallað form (S)-2-etoxý-3-[4-(2-{4-metansúlfonýlfenýl}etoxý)fenýl]própanónsýra
EE200100335A (et) 4-(aminometüül)piperidiinbensamiidid, vaheühendid, farmatseutiline kompositsioon ja nende valmistamismeetodid
DE60226634D1 (de) Segmentierte schreibleitungsarchitektur
NO20023379L (no) Farmasöytisk preparat omfattende premetrexed sammen med monotioglycerol-L-cystein eller tioglykolsyre
DK1599455T3 (da) 4-(3-(2-phenyl-oxazol-4-ylmethoxy)-cyclohexyloxy)-butansyrederivater og beslægtede forbindelser som PPAR modulatorer til behandling af type 2 diabetes og aterosclerose
NO20035236D0 (no) Farmasöytisk kombinasjon omfattende enten (S) -2-etoksy-3 (4- (2- (4-metansulfonyloksyfenyl) etoksy) fenyl) propansyre eller 3- (4- (2- (4-tert-butoksykarbonylaminofenyl) etoksy) fenyl) - (S) -2-
DE602004018622D1 (de) Pharmazeutische zusammensetzung enthaltend 5-methyl-2-2'-(chloro-6'-fluoroanilino)phenylessigsäure
AU2034601A (en) Crystalline form of 3-(4-(2-(4-tert-butoxycarbonylaminophenyl)ethoxy)phenyl)-(s) 2-ethoxy propanoic acid
AU2034701A (en) Comminuted form of 3-(4-(2-(4-tert-butoxycarbonylaminophenyl)ethoxy)phenyl)-(s) 2-ethoxy propanoic
FR2890312B1 (fr) Procede d'obtention d'un principe actif repulpant, principe actif obtenu et compositions cosmetiques l'incluant
EE200300583A (et) Ravimikombinatsioon, mis sisaldab kas (S)-2-etoksü-3-[4-(2-{4-metaansulfonüüloksüfenüül}etoksü)fenüül]propaanhapet või 3-{4-[2-(4-tert-butoksükarbonüülaminofenüül)etoksü]fenüül}-(S)-2-etoksüpropaanhapet ja sulfonüüluureat
AU2001244098A1 (en) Pharmaceutical composition containing 3-(4(2-phenoxazin-10-yl)ethoxy)phenyl)-2-ethoxy propanoicacid
DE60225882D1 (de) Aufzeichnungspapierrolle
FR2829927B1 (fr) Nouvelles compositions cosmetiques et leur procede d'obtention
DE60223759D1 (de) Wälzlager
FR2887148B1 (fr) Procede d'obtention d'un principe actif anti-age et principe actif obtenu
NO20035237D0 (no) Farmasöytisk kombinasjon omfattende enten (S) -2-etoksy-3-(4- (2- (4-metansulfonyloksyfenyl) etoksy) fenyl) propansyre eller 3- (4- (2- (4-tert-butoksykarbonylaminofenyl) etoksy) fenyl)

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application